NCT02513654View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 6, 2015

Primary Completion Date

November 11, 2015

Study Completion Date

November 11, 2015

Conditions
Bipolar Disorder
Interventions
DRUG

Lamotrigine

Lamotrigine dispersible tablets supplied in 3 different strengths 25 mg, 50 mg and 100 mg. These dispersible tablets appear as white or off-white tablets.

Trial Locations (1)

200030

GSK Investigational Site, Shanghai

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02513654 - Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter